Recently published in the journal Nature Medicine (1), results of exploratory research from the open-label phase III INTRIGUE clinical trial…
NOTICIAS
The Vall d’Hebron Institute of Oncology (VHIO) has received 52 grants this year for its research and technical staff that…
Cancer patients in Europe are treated by an array of different specialties and professions: medical oncologists, radiation oncologists, surgical oncologists,…
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
“la Caixa” Foundation has subsidized a new transversal platform for next generation single-cell sequencing: UNderstanding cancer through sIngle cell seQUEncing:…
A study led by IRB Barcelona with the collaboration of different VHIO research groups describes a mechanism by which senescent…
Checkmate 8HW is the first phase III study to assess first-line nivolumab plus ipilimumab in patients with unresectable microsatellite instability-high/mismatch…
Results of the multi-center, randomized, comparator-controlled phase III NETTER-2 trial show that first-line treatment with radioligand therapy 177LU-DOTATATE in combination…
The Vall d’Hebron University Hospital Accredited Health Institute (ISS-IR-HUVH) has been one of those selected for the Fortalece -Salud program…
The biotech company Peptomyc SL and the Vall d’Hebron Institute of Oncology announced today that the public-private collaborators have been…
